Skye Bioscience and Redx Pharma to Merge, Forming Fibrx Therapeutics

Key Facts

In a move aimed at consolidating resources within the biotechnology sector, Skye Bioscience has announced a definitive merger agreement with Redx Pharma to create a new entity named Fibrx Therapeutics. Skye Bioscience is scheduled to execute a 1-for-8 reverse stock split on August 24, 2026, a corporate action designed to meet Nasdaq listing requirements. The combined company will focus on developing innovative fibrosis treatments, with the transaction expected to close in the fourth quarter of 2026.

According to analyst reports, the combined entity has secured $125 million in financing from institutional investors, which is projected to support drug development and operations through 2029. Pre-transaction Redx Pharma equity holders are expected to own approximately 59.75% of the new company, while investors in the concurrent financing will hold about 34.87%. This structural shift comes as Skye Bioscience shares faced immediate retail pressure, dropping 13.5% on the day of the announcement.

The merger is intended to advance the lead drug program, RXC008, through Phase 2 clinical trials, strengthening the company's competitive position in the fibrosis treatment market. Based on market data as of August 19, 2026, specific instrument prices are currently unavailable; however, investors should watch the upcoming reverse split next week as a primary catalyst for share price stabilization.